Erratum: Bcl-xL controls a switch between cell death modes during mitotic arrest (Cell Death and Disease (2014) 5 (e1291) DOI: 10.1038/cddis.2014.251);Bcl-xL controls a switch between cell death modes during mitotic arrest

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Bah, N ^a   Maillet, L ^a   Ryan, J ^b   Dubreil, S ^a   Gautier, F ^a,c,d   Letai, A ^b   Juin, P ^a,c   Barille Nion S ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CELL CYCLE PROTEIN 20; PACLITAXEL; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; ABT-737; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BCL X; SULFONAMIDE;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL DEATH; CELL FATE; CELL PROTECTION; CELL SURVIVAL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRION; MITOSIS; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; AMINO ACID SUBSTITUTION; BREAST NEOPLASMS; CELL CYCLE CHECKPOINT; FEMALE; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; FEMALE; HUMANS; MITOCHONDRIA; MUTATION, MISSENSE; NITROPHENOLS; PIPERAZINES; SULFONAMIDES;

EID: 84903792687     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.436     Document Type: Erratum

References (34)

1. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-393.
2. Weaver BAA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005; 8: 7-12.
3. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006; 16: 1194-1200.
4. Gascoigne KE, Taylor SS. Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111-122.
5. Huang HC, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009; 16: 347-358.
6. Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6: 4610-4617.
7. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the Bcl-2 depencency of cancer cells. Nat Rev Cancer 2013; 13: 455-465.
8. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F et al. Sensitization of Bcl-2 expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 2012; 109: 2766-2771.
9. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012; 21: 547-562.
10. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME et al. Targeting Bcl-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013; 24: 120-129.
11. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
12. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
13. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM et al. Relative mitochondriel priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151: 344-355.
14. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129-1133.
15. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008; 68: 7985-7994.
16. Barillé-Nion S, Bah N, Véquaud E, Juin P. Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy. Anticancer Res 2012; 32: 4225-4233.
17. Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K. BUB1 mediation of caspaseindependent mitotic death determines cell fate. J Cell Biol 2007; 178: 283-296.
18. Shi J, Zhou Y, Huang H-C, Mitchison TJ. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing BCLXL. Cancer Res 2011; 71: 4518-4526.
19. Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L et al. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 2011; 17: 1394-1404.
20. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114.
21. Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1-mediated BCLXL/BCL2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010; 30: 640-656.
22. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S et al. Identification of the major phosphorylation site in BCLXL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 2008; 283: 35517-35525.
23. Sakurikar N, Eichhorn JM, Chambers TC. Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. J Biol Chem 2012; 287: 39193-39204.
24. Basu A, Haldar S. Identification of a novel BCLXL phosphorylation site regulating the sensitivity of taxol-or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003; 538: 41-47.
25. Wang J, Beauchemin M, Bertrand R. Phospho-Bcl-x(L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Cell Cycle 2012; 11: 2159-2169.
26. Sakurikar N, Eichhorn JM, Alford SE, Chambers TC. Identification of a mitotic death signature in cancer cell lines. Cancer Lett 2014; 343: 232-238.
27. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
28. Gautier F, Guillemin Y, Cartron PF, Gallenne T, Cauquil N, Le Diguarher T et al. Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xL. Mol Cell Biol 2011; 31: 832-844.
29. Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011; 145: 104-116.
30. Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ 2010; 17: 1624-1635.
31. Romagnoli M, Trichet V, David C, Clément M, Moreau P, Bataille R et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007; 21: 1070-1078.
32. Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013; 61: 156-164.
33. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014; 4: 362-375.
34. Vo DD, Gautier F, Juin P, Grée R. Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction. Eur J Med Chem 2012; 51: 286-293.